<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371081</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10290</org_study_id>
    <nct_id>NCT04371081</nct_id>
  </id_info>
  <brief_title>Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance</brief_title>
  <official_title>Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japanese society of Congenital Interventional Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing clinical use database surveillance is to observe the&#xD;
      frequency, type, and degree of adverse device effects and adverse events in order to assure&#xD;
      the safety of the medical device, and to collect safety and efficacy information for&#xD;
      evaluating the results of its clinical use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Surveillance will be conducted per the standards required by the Ministry of Health,&#xD;
      Labour and Welfare (MHLW) and in the standards for post-marketing surveillances and studies&#xD;
      [except for those defined in the Ministerial Ordinance on Good Clinical Practice for Medical&#xD;
      Devices (MHLW Ordinance No. 36, 2005)] based on Paragraph 4, Article 23-2-9 (including&#xD;
      application mutatis mutandis per Article 23-2-19 of Revised PAL) of the Law on Securing&#xD;
      Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices, etc. (Law No. 145, 1960,&#xD;
      hereinafter referred to as &quot;Revised PAL&quot;) by the Marketing Authorization Holder or accredited&#xD;
      foreign manufacturer of a medical device defined in Paragraph 1, Article 23-2-5 of Revised&#xD;
      PAL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>The rate of major complications through 180 days after an attempted Piccolo device implant</measure>
    <time_frame>Through 180 days after an attempted Piccolo device implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of effective closure of the ductus arteriosus among subjects with a successful Piccolo implant as assessed by the presence of either a Grade 0 or Grade 1 shunt at the 6-month follow-up by transthoracic echocardiography</measure>
    <time_frame>At the 6-month follow-up</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Amplatzer Piccolo Occluder</arm_group_label>
    <description>Amplatzer Piccolo Occluder device implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amplatzer Piccolo Occluder</intervention_name>
    <description>Interventional placement of vascular occluder</description>
    <arm_group_label>Amplatzer Piccolo Occluder</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with patent ductus arteriosus (PDA) in whom an Amplatzer™ Piccolo Occluder&#xD;
        (Piccolo) implant was attempted will be included in this registry.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The device is used to percutaneously close the PDA of a patient who meets all of the&#xD;
        following:&#xD;
&#xD;
          -  PDA ≤4 mm in diameter&#xD;
&#xD;
          -  PDA ≥3 mm in length&#xD;
&#xD;
          -  Weight ≥700 g&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;3 days&#xD;
&#xD;
          -  Coarctation of the aorta&#xD;
&#xD;
          -  Left pulmonary artery stenosis&#xD;
&#xD;
          -  Cardiac output that is dependent on right to left shunt through the PDA due to&#xD;
             pulmonary hypertension&#xD;
&#xD;
          -  Thrombus in the implant site, or sign of venous thrombus in a vessel in which the&#xD;
             occluder is inserted and delivered&#xD;
&#xD;
          -  Endocarditis, or infection that can cause bacteremia&#xD;
&#xD;
          -  Allergic or potentially allergic to nickel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuri Masui</last_name>
    <phone>+81-3-3524-1792</phone>
    <phone_ext>1799</phone_ext>
    <email>yuri.masui@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideshi Tomita, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

